Musi waGumiguru 12, 2024, JYMed's Liraglutide API yakawana Chitupa Chakanyorwa Chisimbiso (WC), ichimaka nhanho yakakosha yekuenda kunze kwenyika kweAPI kumusika weEU.
TheWC (Yakanyorwa Simbiso)chinhu chinosungirwa kuburitsa kunze kwenyika maAPI kubva kune dzisiri dzeEU nyika kuenda kumusika weEU. Chitupa ichi chakapihwa nechiremera chekutonga chenyika inotumira kunze kwenyika, chitupa ichi chinovimbisa kuti iyo inotengeswa kunze kwenyika API inoenderana neYakanaka Kugadzira Kudzidzira (GMP)zviyero zvakatarwa neEU. Inobata basa rakakosha mukuona kunaka uye kuchengetedzeka kweAPIs uye yakakosha kune dzisiri dzeEU nyika dziri kutsvaga mukana kumusika weEU wemishonga.
Kugamuchirwa kweWC chitupa cheLiraglutide API hakungoratidzi chete kucherechedzwa zviri pamutemo kwemhando uye kuchengetedzeka kwezvigadzirwa zveJYMed asi zvakare kunosimudzira kugona kwekambani kuwedzera kuvepo kwayo mumusika weEU API. Kubudirira uku kunosimbisa chinzvimbo cheJYMed muindasitiri yemishonga yepasi rose, ichipa mikana mikuru yebudiriro uye kuwedzera mukurumbira wayo wepasirese.
About JYMed
Shenzhen JYMed Technology Co., Ltd. (inozonzi JYMed) yakavambwa muna 2009, ichishanda mukutsvaga, kusimudzira, kugadzira, uye kutengesa kwepeptides uye zvigadzirwa zvine chekuita nepeptide. Iine imwe nzvimbo yekutsvagisa uye matatu makuru mabhesi ekugadzira, JYMed ndeimwe yevagadziri vakakura vemakemikari synthesized peptide APIs muChina. Iyo kambani yepakati R&D timu inozvirumbidza pamusoro pemakore makumi maviri echiitiko muindasitiri yepeptide uye yakabudirira kupfuura FDA ongororo kaviri. JYMed's yakazara uye inoshanda peptide maindasitiri system inopa vatengi huwandu hwakazara hwesevhisi, kusanganisira kusimudzira uye kugadzirwa kweanorapa peptides, veterinary peptides, antimicrobial peptides, uye cosmetic peptides, pamwe nekunyoresa uye kudzora tsigiro.
Main Bhizinesi Mabasa
1.Domestic uye pasi rose kunyoresa peptide APIs
2.Veterinary uye cosmetic peptides
3.Custom peptides uye CRO, CMO, OEM mabasa
4.PDC mishonga (peptide-radionuclide, peptide-diki molecule, peptide-protein, peptide-RNA)
Pamusoro peTirzepatide, JYMed yakaendesa mafirita ekunyoresa neFDA neCDE kune akati wandei zvimwe zvigadzirwa zveAPI, zvinosanganisira parizvino inozivikanwa GLP-1RA kirasi mishonga yakadai seSemaglutide neLiraglutide. Vatengi venguva yemberi vachishandisa zvigadzirwa zveJYMed vanozokwanisa kunongedzera zvakananga nhamba yeCDE yekunyoresa kana nhamba yefaira reDMF pavanotumira zvikumbiro zvekunyoresa kuFDA kana CDE. Izvi zvichaderedza zvakanyanya nguva inodiwa pakugadzirira magwaro ekunyorera, pamwe nenguva yekuongorora uye mutengo wekuongorora chigadzirwa.
Taura nesu
Shenzhen JYMed Technology Co., Ltd.
Kero: 8th & 9th Floors, Building 1, Shenzhen Biomedical Innovation Industrial Park, Nhamba 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen
Nharembozha: +86 755-26612112
Webhusaiti:http://www.jymedtech.com/
Nguva yekutumira: Oct-17-2024